Tag: xerostomia therapeutics market research

Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.

#Xerostomia Therapeutics Market Growth From $2.35 Billion In 2026 To $2.78 Billion By 2030 At A CAGR Of 4.3%#_x000D_

The xerostomia therapeutics market has shown consistent expansion over recent years. Its valuation is set to increase from $2.24 billion in 2025 to $2.35 billion in 2026, advancing at a compound annual growth rate (CAGR) of 5.0%. The market’s historical growth can be attributed to an aging population, the extensive use of xerogenic drugs, a rise in the prevalence of chronic diseases, heightened dental awareness, and hospital-based symptom management._x000D_

_x000D_

The xerostomia therapeutics market is projected to experience consistent expansion over the coming years, reaching $2.79 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 4.3%. This projected growth during the forecast period is due to factors such as increased availability of OTC products, a rise in side effects from cancer therapies, growing self-medication behaviors, an expanding network of pharmacies, and a greater emphasis on treatments that enhance quality of life. Key developments anticipated in this period include a surge in medication-induced dry mouth cases, increasing demand for over-the-counter remedies, wider acceptance of artificial saliva products, the growth of retail and mail-order pharmacies, and a heightened focus on managing oral symptoms._x000D_

_x000D_

#Get A Free Sample Report With In-Depth Market Insights:#_x000D_

https://thebusinessresearchcompany.com/sample_request?id=47575567&type=smp&name=Xerostomia%20Therapeutics%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR_x000D_

_x000D_

#Xerostomia Therapeutics Market Growth Drivers: What’s Behind The Acceleration?#_x000D_

The xerostomia therapeutics market is anticipated to expand due to the increasing occurrence of chronic diseases. These are enduring medical conditions that last for extended periods, typically advancing gradually and necessitating continuous care. The growing incidence of chronic ailments largely stems from inactive lifestyles, as insufficient physical activity leads to issues such as obesity, heart conditions, diabetes, and other persistent health problems. Xerostomia treatments assist individuals with chronic diseases by relieving dry mouth discomfort and enhancing oral hygiene, nutritional intake, and medication compliance, all of which are crucial for managing long-term health issues. For example, data from June 2024, provided by the National Health Service, a UK government department, revealed that 3,615,330 patients registered with a general practitioner (GP) were diagnosed with non-diabetic hyperglycemia or pre-diabetes (a state of elevated blood sugar not yet classified as diabetes) in 2023. This represented an 18% rise from 3,065,825 cases recorded in 2022. Consequently, the rising burden of chronic diseases is propelling the growth of the xerostomia therapeutics market._x000D_

_x000D_

#Xerostomia Therapeutics Market Segment Landscape: Which Areas Lead Development?#_x000D_

The xerostomia therapeutics market covered in this report is segmented – _x000D_

_x000D_

1) By Type: Artificial Saliva Or Saliva Substitutes, Salivary Stimulants_x000D_

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Drug Stores, Mail Order Pharmacies, Hypermarkets And Supermarkets_x000D_

3) By End-User: Adult, Pediatric_x000D_

_x000D_

Subsegments:_x000D_

1) By Artificial Saliva Or Saliva Substitutes: Oral Sprays, Gels, Lozenges, Mouthwashes _x000D_

2) By Salivary Stimulants: Prescription Drugs, Over-The-Counter (Otc) Products, Chewing Gums And Lozenges_x000D_

_x000D_

#Xerostomia Therapeutics Market Trends: What’s Defining The Industry’s Next Phase?#_x000D_

Companies operating significantly in the xerostomia therapeutics market are concentrating on patient-friendly, non-invasive treatment options, such as oral sprays, which provide targeted topical lubrication and a protective barrier coverage throughout the mouth to ease dry-mouth symptoms and support oral well-being. Oral sprays designed for xerostomia are formulations applied as a fine mist directly onto the oral mucosa (tongue, palate, inner cheeks), either forming a hydrating film or a lipid-based coating to reduce moisture evaporation, enhance lubrication during chewing, swallowing, and speaking, and deliver extended relief to patients experiencing dry mouth. As an illustration, in July 2023, K Pharmaceuticals, a pharmaceutical company based in the US, launched Aquoral, a clinically-proven oral spray for managing xerostomia. This product utilizes patented Oxidized Glycerol Triesters (OGT) lipid technology to create a long-lasting protective barrier over the oral cavity, providing relief for up to six hours with just two quick sprays, which lessens the requirement for frequent reapplication compared to aqueous-based treatments._x000D_

_x000D_

#Xerostomia Therapeutics Market Industry Leaders And Competitive Landscape#_x000D_

Major companies operating in the xerostomia therapeutics market are GlaxoSmithKline plc, Colgate-Palmolive Company, Sun Pharmaceutical Industries Ltd., Cipla Ltd., Synedgen Inc., Mission Pharmacal Company, Dentaid Ltd., Sunstar Suisse S.A., Forward Science Holding Inc., OraCoat, Oralieve UK Ltd., OraPharma Inc., OraVital Inc., Saliwell Limited, Bayer AG, 3M Company, Church & Dwight Co. Inc., Hikma Pharmaceuticals PLC, Lupin Limited, Teva Pharmaceutical Industries Ltd. _x000D_

_x000D_

#View The Full Xerostomia Therapeutics Market Report:#_x000D_

https://thebusinessresearchcompany.com/report/xerostomia-therapeutics-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR_x000D_

_x000D_

#Xerostomia Therapeutics Market Regional Analysis: Which Geography Leads On Revenue?#_x000D_

North America was the largest region in the xerostomia therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the xerostomia therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#Reach Out To Our Team:#_x000D_

_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas: +1 310-496-7795_x000D_

Asia: +44 7882 955267 & +91 8897263534_x000D_

Europe: +44 7882 955267_x000D_

Email us at: marketing@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Xerostomia Therapeutics Market Size, Value And Growth Trends Through 2030

The xerostomia therapeutics market has experienced consistent growth over the past several years. Projected figures indicate an expansion from $2.24 billion in 2025 to $2.35 billion in 2026, reflecting a compound annual growth rate (CAGR) of 5.0%. This upward trend during the historical period has been driven by factors such as an aging demographic, the extensive use of medications that induce dry mouth, a growing incidence of chronic health conditions, heightened awareness of dental health, and the management of symptoms within hospital settings.

The xerostomia therapeutics market is projected to experience consistent expansion over the coming years. By 2030, it is anticipated to reach $2.79 billion, registering a compound annual growth rate (CAGR) of 4.3%. This anticipated growth during the forecast period is driven by factors such as the increased availability of over-the-counter products, a rise in side effects linked to cancer therapies, a growing tendency toward self-medication, the broadening of pharmacy networks, and an enhanced emphasis on treatments that improve quality of life. Key trends shaping this period include a higher incidence of dry mouth caused by medications, a growing preference for over-the-counter remedies, a wider adoption of artificial saliva solutions, the expansion of both retail and mail-order pharmacy services, and a stronger focus on managing oral symptoms.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15700&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Xerostomia Therapeutics Market Development Factors: Which Trends Are Supporting Demand?

The increasing occurrence of chronic illnesses is anticipated to boost the expansion of the xerostomia therapeutics market in the upcoming period. Chronic illnesses are long-term medical conditions that last for months or years, often developing gradually and demanding continuous care. Their rising frequency is largely attributed to inactive lifestyles, since insufficient regular physical activity leads to obesity, heart disease, diabetes, and other persistent health issues. Xerostomia therapeutics assist in managing chronic diseases by relieving dry mouth symptoms and enhancing oral health, dietary intake, and medication compliance—essential aspects for controlling long-term conditions. For example, in June 2024, data from the National Health Service, a UK governmental organization, showed that 3,615,330 individuals registered with a general practitioner (GP) had non-diabetic hyperglycemia or pre-diabetes in 2023, an 18% rise from 3,065,825 cases in 2022. Consequently, the growing prevalence of chronic diseases is fueling the advancement of the xerostomia therapeutics market.

Xerostomia Therapeutics Market Driver: Growing Geriatric Population Boosting Demand Due to Higher Dry-Mouth Risk

The expanding elderly population is set to drive the growth of the xerostomia therapeutics market in the future. The term geriatric population describes the increasing number of individuals aged 65 and older worldwide. This demographic shift is fueled by falling birth rates and longer life expectancies globally. The xerostomia therapeutics sector aids older adults by offering saliva-stimulating products and oral moisturizers that alleviate dry mouth, facilitating easier chewing, swallowing, and proper nutrition. As an illustration, in July 2024, the House of Commons Library within the UK Parliament reported that in 2022, 12.7 million people in the UK were 65 or older—19% of the total population—with projections indicating a rise to 22.1 million by 2072, making up 27% of the population. Thus, the aging population is propelling the expansion of the xerostomia therapeutics market.

Xerostomia Therapeutics Market Segment Outlook: Which Categories Are Expanding The Fastest?

The xerostomia therapeutics market covered in this report is segmented –

1) By Type: Artificial Saliva Or Saliva Substitutes, Salivary Stimulants

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Drug Stores, Mail Order Pharmacies, Hypermarkets And Supermarkets

3) By End-User: Adult, Pediatric

Subsegments:

1) By Artificial Saliva Or Saliva Substitutes: Oral Sprays, Gels, Lozenges, Mouthwashes

2) By Salivary Stimulants: Prescription Drugs, Over-The-Counter (Otc) Products, Chewing Gums And Lozenges

Xerostomia Therapeutics Market Transformation Trends: Which Innovations Are Driving Change?

Leading players in the xerostomia therapeutics space are increasingly prioritizing non-invasive, patient-friendly solutions like oral sprays, which deliver targeted topical lubrication and create a protective barrier throughout the mouth to alleviate dry-mouth symptoms while promoting better oral health. These oral sprays for xerostomia are formulated as a fine mist applied directly to oral tissues, including the tongue, palate, and inner cheeks, where they establish either a hydrating film or a lipid-based coating that curbs moisture loss, improves lubrication during eating, swallowing, and speaking, and provides extended relief for individuals experiencing chronic dry mouth. As a case in point, in July 2023, K Pharmaceuticals, a US-based pharmaceutical company, introduced Aquoral, a clinically validated oral spray designed to manage xerostomia. This product utilizes patented Oxidized Glycerol Triesters (OGT) lipid technology to produce a durable protective shield over the oral cavity, delivering up to six hours of symptom relief with just two quick sprays, thereby minimizing the frequency of reapplication when compared to water-based alternatives.

Xerostomia Therapeutics Market Key Companies And Competitive Benchmarking

Major companies operating in the xerostomia therapeutics market are GlaxoSmithKline plc, Colgate-Palmolive Company, Sun Pharmaceutical Industries Ltd., Cipla Ltd., Synedgen Inc., Mission Pharmacal Company, Dentaid Ltd., Sunstar Suisse S.A., Forward Science Holding Inc., OraCoat, Oralieve UK Ltd., OraPharma Inc., OraVital Inc., Saliwell Limited, Bayer AG, 3M Company, Church & Dwight Co. Inc., Hikma Pharmaceuticals PLC, Lupin Limited, Teva Pharmaceutical Industries Ltd.

Access The Complete Xerostomia Therapeutics Market Report:

https://www.thebusinessresearchcompany.com/report/xerostomia-therapeutics-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Xerostomia Therapeutics Market Regional Analysis And Leading Geography

North America was the largest region in the xerostomia therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the xerostomia therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Is The Expected Market Size Of The Xerostomia Therapeutics Market In 2026 And How Much Will It Reach By 2030?

The xerostomia therapeutics market size has shown consistent expansion in recent years. It is projected to increase from $2.24 billion in 2025 to $2.35 billion in 2026, at a compound annual growth rate (CAGR) of 5.0%. This historical growth can be attributed to an aging population, the widespread use of xerogenic drugs, a rising prevalence of chronic diseases, enhanced dental awareness, and hospital-based symptom management.

The xerostomia therapeutics market size is projected to experience consistent expansion in the coming years, reaching $2.79 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 4.3%. This anticipated growth during the forecast period is fueled by factors such as increased availability of OTC products, the growing prevalence of cancer therapy side effects, an uptick in self-medication practices, the widening reach of pharmacy networks, and a greater emphasis on treatments that enhance quality of life. Key developments expected within this period involve a rise in medication-induced dry mouth cases, increasing consumer demand for over-the-counter remedies, broader acceptance of artificial saliva solutions, the expansion of retail and mail-order pharmacy operations, and a sharper focus on managing oral symptoms.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15700&type=smp

Which Strategic Drivers Are Supporting The Xerostomia Therapeutics Market Development?

The increasing occurrence of chronic illnesses is anticipated to fuel the expansion of the xerostomia therapeutics market in the coming years. Chronic diseases are defined as enduring medical conditions that persist for many months or years, often progressing gradually and requiring continuous care. The primary cause of the growing incidence of chronic diseases is sedentary lifestyles, as a lack of regular physical activity contributes to health issues such as obesity, cardiovascular problems, diabetes, and other prolonged health conditions. Xerostomia therapeutics assist individuals with chronic diseases by relieving dry mouth symptoms and enhancing oral health, nutritional intake, and adherence to medication, all of which are vital aspects of managing long-term health conditions. For example, in June 2024, data from the National Health Service, a UK-based government department, revealed that 3,615,330 individuals registered with a general practitioner (GP) were diagnosed with non-diabetic hyperglycemia or pre-diabetes (a condition characterized by elevated blood sugar levels, not yet severe enough to be classified as diabetes) in 2023, representing an 18% rise from 3,065,825 cases recorded in 2022. Consequently, the rising prevalence of chronic diseases is a key factor driving the growth of the xerostomia therapeutics market.

How Are Different Segment Groups Identified Within The Xerostomia Therapeutics Market?

The xerostomia therapeutics market covered in this report is segmented –

1) By Type: Artificial Saliva Or Saliva Substitutes, Salivary Stimulants

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Drug Stores, Mail Order Pharmacies, Hypermarkets And Supermarkets

3) By End-User: Adult, Pediatric

Subsegments:

1) By Artificial Saliva Or Saliva Substitutes: Oral Sprays, Gels, Lozenges, Mouthwashes

2) By Salivary Stimulants: Prescription Drugs, Over-The-Counter (Otc) Products, Chewing Gums And Lozenges

Which Trends Are Supporting The Evolution Of The Xerostomia Therapeutics Market?

Leading companies in the xerostomia therapeutics market are focusing on developing patient-friendly, non-invasive treatments, such as oral sprays that provide precise topical lubrication and protective barrier coverage across the mouth to relieve dry-mouth symptoms and support oral health. Oral sprays for xerostomia are formulations delivered as a fine mist directly onto the oral mucosa (tongue, palate, inner cheeks), forming either a hydrating film or a lipid-based coating to reduce moisture evaporation, enhance lubrication during chewing, swallowing, and speaking, and deliver longer duration relief in patients prone to dry mouth. For instance, in July 2023, K Pharmaceuticals, a US-based pharmaceutical company, launched Aquoral, a clinically-proven oral spray for managing xerostomia that utilizes patented Oxidized Glycerol Triesters (OGT) lipid technology to form a long-lasting protective barrier over the oral cavity, offering up to six hours of relief, enabling two quick sprays, and reducing the need for frequent reapplication compared to aqueous-based treatments.

Which Companies Are Engaged In The Xerostomia Therapeutics Market Environment?

Major companies operating in the xerostomia therapeutics market are GlaxoSmithKline plc, Colgate-Palmolive Company, Sun Pharmaceutical Industries Ltd., Cipla Ltd., Synedgen Inc., Mission Pharmacal Company, Dentaid Ltd., Sunstar Suisse S.A., Forward Science Holding Inc., OraCoat, Oralieve UK Ltd., OraPharma Inc., OraVital Inc., Saliwell Limited, Bayer AG, 3M Company, Church & Dwight Co. Inc., Hikma Pharmaceuticals PLC, Lupin Limited, Teva Pharmaceutical Industries Ltd.

Access The Complete Xerostomia Therapeutics Market Report:

https://www.thebusinessresearchcompany.com/report/xerostomia-therapeutics-global-market-report

Which Region Contributes The Most To The Xerostomia Therapeutics Market?

North America was the largest region in the xerostomia therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the xerostomia therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Xerostomia Therapeutics Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=15700&type=smp

Browse Through More Reports Similar to the Global Xerostomia Therapeutics Market 2026, By The Business Research Company

Xerostomia Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/xerostomia-therapeutics-global-market-report

Leukemia Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/leukemia-therapeutics-global-market-report

Mantle Cell Lymphoma Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/mantle-cell-lymphoma-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Does The Market Size Of The Xerostomia Therapeutics Market Compare Between 2026 And 2030?

The xerostomia therapeutics market has demonstrated steady expansion in recent years. It is projected to increase from $2.24 billion in 2025 to $2.35 billion in 2026, at a compound annual growth rate (CAGR) of 5.0%. Historically, this growth can be attributed to an aging population, the widespread use of xerogenic drugs, an increasing prevalence of chronic diseases, heightened dental awareness, and hospital-based symptom management.

The xerostomia therapeutics market is projected to experience consistent expansion over the upcoming years. This market is anticipated to reach $2.79 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 4.3%. Factors contributing to this growth during the projection period include an increase in the availability of over-the-counter products, the growing incidence of side effects from cancer therapies, evolving self-medication practices, broader pharmacy network reach, and an elevated emphasis on treatments improving quality of life. Key trends defining the forecast period encompass a higher occurrence of medication-related dry mouth, a surging need for over-the-counter remedies, increased acceptance of artificial saliva solutions, the proliferation of retail and mail-order pharmacies, and a stronger concentration on managing oral symptoms.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15700&type=smp

What Factors Are Contributing To The Growth Of The Xerostomia Therapeutics Market?

The increasing occurrence of chronic illnesses is anticipated to propel the expansion of the xerostomia therapeutics market moving forward. Chronic diseases are defined as long-term medical conditions that persist for many months or years, often progressing slowly and demanding ongoing management. The primary reason for their growing prevalence is sedentary lifestyles, as a lack of regular physical activity contributes to conditions such as obesity, cardiovascular problems, and diabetes. Xerostomia therapeutics play a supportive role in managing chronic diseases by alleviating dry mouth symptoms, which in turn improves oral health, nutrition, and adherence to medication, all crucial elements in handling long-term conditions. For instance, in June 2024, according to the National Health Service, a UK-based government department, 3,615,330 individuals registered with a general practitioner (GP) were diagnosed with non-diabetic hyperglycemia or pre-diabetes (a condition with elevated blood sugar levels, not high enough to be classified as diabetes) in 2023, showing an 18% increase from 3,065,825 cases in 2022. Consequently, the rising prevalence of chronic diseases is a significant driver for the growth of the xerostomia therapeutics market.

How Is The Xerostomia Therapeutics Market Categorized Across Its Segment Groups?

The xerostomia therapeutics market covered in this report is segmented –

1) By Type: Artificial Saliva Or Saliva Substitutes, Salivary Stimulants

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Drug Stores, Mail Order Pharmacies, Hypermarkets And Supermarkets

3) By End-User: Adult, Pediatric

Subsegments:

1) By Artificial Saliva Or Saliva Substitutes: Oral Sprays, Gels, Lozenges, Mouthwashes

2) By Salivary Stimulants: Prescription Drugs, Over-The-Counter (Otc) Products, Chewing Gums And Lozenges

What Trends Are Shaping The Future Of The Xerostomia Therapeutics Market?

Leading companies in the xerostomia therapeutics market are prioritizing patient-friendly, non-invasive solutions, such as oral sprays, which deliver precise topical lubrication and form a protective barrier across the mouth to alleviate dry-mouth symptoms and support overall oral health. These oral sprays for xerostomia are formulations applied as a fine mist directly onto the oral mucosa (tongue, palate, inner cheeks), either creating a hydrating film or a lipid-based coating to reduce moisture evaporation, improve lubrication during chewing, swallowing, and speaking, and offer more prolonged relief for individuals prone to dry mouth. For example, in July 2023, K Pharmaceuticals, a US-based pharmaceutical company, introduced Aquoral, a clinically-proven oral spray designed for xerostomia management that employs patented Oxidized Glycerol Triesters (OGT) lipid technology to establish a long-lasting protective barrier over the oral cavity, providing relief for up to six hours with just two quick sprays, thereby reducing the need for frequent reapplication compared to water-based treatments.

Which Firms Are Influencing Competition In The Xerostomia Therapeutics Market?

Major companies operating in the xerostomia therapeutics market are GlaxoSmithKline plc, Colgate-Palmolive Company, Sun Pharmaceutical Industries Ltd., Cipla Ltd., Synedgen Inc., Mission Pharmacal Company, Dentaid Ltd., Sunstar Suisse S.A., Forward Science Holding Inc., OraCoat, Oralieve UK Ltd., OraPharma Inc., OraVital Inc., Saliwell Limited, Bayer AG, 3M Company, Church & Dwight Co. Inc., Hikma Pharmaceuticals PLC, Lupin Limited, Teva Pharmaceutical Industries Ltd.

Get The Full Xerostomia Therapeutics Market Report:

https://www.thebusinessresearchcompany.com/report/xerostomia-therapeutics-global-market-report

Which Region Accounts For The Largest Portion Of The Xerostomia Therapeutics Market?

North America was the largest region in the xerostomia therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the xerostomia therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Xerostomia Therapeutics Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/xerostomia-therapeutics-global-market-report

Browse Through More Reports Similar to the Global Xerostomia Therapeutics Market 2026, By The Business Research Company

Xerostomia Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/xerostomia-therapeutics-global-market-report

Leukemia Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/leukemia-therapeutics-global-market-report

Mantle Cell Lymphoma Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/mantle-cell-lymphoma-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Increase Is Anticipated For The Xerostomia Therapeutics Market Over The 2026–2030 Period?

The xerostomia therapeutics market has experienced consistent expansion over recent years. It is projected to increase from $2.24 billion in 2025 to $2.35 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 5.0%. This market’s historical growth can be attributed to factors such as an aging population, the widespread use of xerogenic drugs, the rising prevalence of chronic diseases, increased dental awareness, and hospital-based symptom management.

The xerostomia therapeutics market size is projected to experience consistent growth over the coming years. It is anticipated to expand to $2.79 billion by 2030, showing a compound annual growth rate (CAGR) of 4.3%. This expansion during the forecast period is attributable to factors such as increased availability of over-the-counter (OTC) products, a rise in side effects from cancer therapies, growing self-medication tendencies, broader pharmacy network expansion, and an elevated emphasis on quality of life treatments. Significant trends during this period encompass a rising incidence of dry mouth caused by medication, an increasing demand for over-the-counter therapies, greater adoption of artificial saliva products, the proliferation of retail and mail-order pharmacies, and a heightened focus on managing oral symptoms.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15700&type=smp

What Underlying Factors Are Accelerating The Growth Of The Xerostomia Therapeutics Market?

The increasing occurrence of chronic illnesses is anticipated to fuel the expansion of the xerostomia therapeutics market moving forward. These long-term medical conditions persist for extended periods, often developing gradually and necessitating continuous care. A key factor behind the growing prevalence of chronic diseases is inactive lifestyles, which contribute to issues such as obesity, cardiovascular problems, and diabetes. Xerostomia treatments assist individuals with chronic conditions by easing dry mouth symptoms, thereby enhancing oral health, nutritional intake, and adherence to medications, all vital for managing persistent health issues. For example, as reported by the National Health Service in June 2024, a UK-based government department, 3,615,330 individuals registered with a general practitioner (GP) had a diagnosis of non-diabetic hyperglycemia or pre-diabetes in 2023. This condition, characterized by elevated blood sugar levels not yet meeting diabetes criteria, represented an 18% increase from 3,065,825 cases recorded in 2022. Consequently, the rising incidence of chronic diseases is propelling the growth of the xerostomia therapeutics market.

How Is The Xerostomia Therapeutics Market Segmented Across Key Categories?

The xerostomia therapeutics market covered in this report is segmented –

1) By Type: Artificial Saliva Or Saliva Substitutes, Salivary Stimulants

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Drug Stores, Mail Order Pharmacies, Hypermarkets And Supermarkets

3) By End-User: Adult, Pediatric

Subsegments:

1) By Artificial Saliva Or Saliva Substitutes: Oral Sprays, Gels, Lozenges, Mouthwashes

2) By Salivary Stimulants: Prescription Drugs, Over-The-Counter (Otc) Products, Chewing Gums And Lozenges

Which Upcoming Trends Are Expected To Influence The Xerostomia Therapeutics Market?

Companies prominent in the xerostomia therapeutics market are prioritizing patient-centric, non-invasive therapies, particularly oral sprays, which offer accurate topical lubrication and a protective coating throughout the mouth to alleviate dry-mouth indications and bolster oral well-being. These xerostomia-specific oral sprays are preparations dispensed as a fine mist directly onto the oral mucous membranes (such as the tongue, palate, and inner cheeks), creating either a hydrating layer or a lipid-based film. This action helps to diminish moisture loss, improve lubrication during activities like chewing, swallowing, and speaking, and provide sustained relief for individuals susceptible to dry mouth. An example is K Pharmaceuticals, a US-based pharmaceutical company, which introduced Aquoral in July 2023. This clinically validated oral spray for xerostomia management employs patented Oxidized Glycerol Triesters (OGT) lipid technology to establish a durable protective barrier within the oral cavity, delivering up to six hours of relief with just two quick sprays, thereby decreasing the necessity for repeated applications compared to water-based alternatives.

Who Are The Dominant Players Shaping The Xerostomia Therapeutics Market Landscape?

Major companies operating in the xerostomia therapeutics market are GlaxoSmithKline plc, Colgate-Palmolive Company, Sun Pharmaceutical Industries Ltd., Cipla Ltd., Synedgen Inc., Mission Pharmacal Company, Dentaid Ltd., Sunstar Suisse S.A., Forward Science Holding Inc., OraCoat, Oralieve UK Ltd., OraPharma Inc., OraVital Inc., Saliwell Limited, Bayer AG, 3M Company, Church & Dwight Co. Inc., Hikma Pharmaceuticals PLC, Lupin Limited, Teva Pharmaceutical Industries Ltd.

Read the full xerostomia therapeutics market report here:

https://www.thebusinessresearchcompany.com/report/xerostomia-therapeutics-global-market-report

Which Region Is Projected To Dominate The Xerostomia Therapeutics Market During The Forecast Period?

North America was the largest region in the xerostomia therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the xerostomia therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Xerostomia Therapeutics Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=15700&type=smp

Browse Through More Reports Similar to the Global Xerostomia Therapeutics Market 2026, By The Business Research Company

Xerostomia Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/xerostomia-therapeutics-global-market-report

Leukemia Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/leukemia-therapeutics-global-market-report

Mantle Cell Lymphoma Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/mantle-cell-lymphoma-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the xerostomia therapeutics market from 2026–2035 with trusted insights from The Business Research Company

How much is the Xerostomia Therapeutics Market valued at in 2026, and what valuation is forecast for 2030?

The xerostomia therapeutics market has experienced consistent expansion in recent years. It is projected to grow from $2.24 billion in 2025 to $2.35 billion in 2026, at a compound annual growth rate (CAGR) of 5.0%. Historically, this growth has been driven by factors including the aging population, widespread use of xerogenic drugs, rising prevalence of chronic diseases, increased dental awareness, and hospital-based symptom management.

The xerostomia therapeutics market is projected to experience consistent expansion in the coming years, with its size anticipated to reach $2.79 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 4.3%. This anticipated growth during the forecast period is driven by factors such as enhanced availability of over-the-counter (OTC) products, the rise in side effects from cancer therapies, evolving self-medication practices, the widening reach of pharmacy networks, and an increased emphasis on quality of life treatments. Key developments expected in the forecast period involve a higher occurrence of medication-induced dry mouth, an escalating need for over-the-counter treatments, greater uptake of artificial saliva solutions, the expansion of both retail and mail-order pharmacy services, and a heightened focus on managing oral symptoms.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15700&type=smp

What Drivers Are Influencing The Growth Of The Xerostomia Therapeutics Market?

The increasing occurrence of chronic diseases is anticipated to fuel the expansion of the xerostomia therapeutics market. Chronic diseases are defined as prolonged medical conditions that persist for many months or years, often developing gradually and necessitating continuous care. The primary reason behind the growing incidence of chronic diseases is sedentary lifestyles, as a lack of regular physical activity contributes to conditions such as obesity, cardiovascular problems, and diabetes. Xerostomia therapeutics support individuals with chronic diseases by relieving symptoms of dry mouth, thereby enhancing oral health, nutritional intake, and adherence to medication, all of which are vital for managing long-term ailments. For example, according to the UK-based government department National Health Service in June 2024, 3,615,330 individuals registered with a general practitioner were identified with non-diabetic hyperglycemia or pre-diabetes (a condition characterized by elevated blood sugar levels, not yet meeting the criteria for diabetes) in 2023. This figure represents an 18% increase from 3,065,825 cases recorded in 2022. Consequently, the rising prevalence of chronic diseases is propelling the growth of the xerostomia therapeutics market.

How Is The Xerostomia Therapeutics Market Organized Into Various Segments?

The xerostomia therapeutics market covered in this report is segmented –

1) By Type: Artificial Saliva Or Saliva Substitutes, Salivary Stimulants

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Drug Stores, Mail Order Pharmacies, Hypermarkets And Supermarkets

3) By End-User: Adult, Pediatric

Subsegments:

1) By Artificial Saliva Or Saliva Substitutes: Oral Sprays, Gels, Lozenges, Mouthwashes

2) By Salivary Stimulants: Prescription Drugs, Over-The-Counter (Otc) Products, Chewing Gums And Lozenges

Which Trends Are Influencing The Development Of The Xerostomia Therapeutics Market?

Leading companies in the xerostomia therapeutics market are prioritizing non-invasive, patient-friendly treatments, such as oral sprays designed to offer precise topical lubrication and a protective barrier throughout the mouth to alleviate dry-mouth symptoms and support overall oral health. These oral sprays for xerostomia are formulations delivered as a fine mist directly onto the oral mucosa (tongue, palate, inner cheeks), forming either a hydrating film or a lipid-based coating. This action aims to reduce moisture evaporation, enhance lubrication during activities like chewing, swallowing, and speaking, and provide longer-lasting relief for patients experiencing dry mouth. For instance, in July 2023, K Pharmaceuticals, a US-based pharmaceutical company, introduced Aquoral. This clinically-proven oral spray for xerostomia utilizes patented Oxidized Glycerol Triesters (OGT) lipid technology to establish a long-lasting protective barrier over the oral cavity, delivering up to six hours of relief with just two quick sprays, and thereby reducing the need for frequent reapplication compared to aqueous-based treatments.

Who Are The Top-Performing Companies In The Xerostomia Therapeutics Market In Recent Years?

Major companies operating in the xerostomia therapeutics market are GlaxoSmithKline plc, Colgate-Palmolive Company, Sun Pharmaceutical Industries Ltd., Cipla Ltd., Synedgen Inc., Mission Pharmacal Company, Dentaid Ltd., Sunstar Suisse S.A., Forward Science Holding Inc., OraCoat, Oralieve UK Ltd., OraPharma Inc., OraVital Inc., Saliwell Limited, Bayer AG, 3M Company, Church & Dwight Co. Inc., Hikma Pharmaceuticals PLC, Lupin Limited, Teva Pharmaceutical Industries Ltd.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/xerostomia-therapeutics-global-market-report

Which Region Currently Holds The Largest Share Of The Xerostomia Therapeutics Market?

North America was the largest region in the xerostomia therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the xerostomia therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Xerostomia Therapeutics Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=15700&type=smp

Browse Through More Reports Similar to the Global Xerostomia Therapeutics Market 2026, By The Business Research Company

Xerostomia Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/xerostomia-therapeutics-global-market-report

Leukemia Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/leukemia-therapeutics-global-market-report

Mantle Cell Lymphoma Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/mantle-cell-lymphoma-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the generic central nervous system drugs market from 2025–2034 with trusted insights from The Business Research Company

What Are The Market Size Estimates For The Generic Central Nervous System Drugs Market Now And By 2029?

The xerostomia therapeutics market has demonstrated consistent expansion in recent years. It is anticipated to increase from $2.14 billion in 2024 to $2.24 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 4.7%. The historical growth trajectory can be attributed to several factors, including the increasing incidences of xerostomia in the geriatric population, ongoing research and development efforts for efficient xerostomia products, growing awareness about xerostomia-related products, an increase in various medical conditions, and the rising prevalence of chronic diseases.

The xerostomia therapeutics market size is expected to experience steady growth in the coming years, projected to reach $2.69 billion in 2029, exhibiting a compound annual growth rate (CAGR) of 4.7%. This expansion during the forecast period is attributable to several factors, including the easy availability of cost-effective medications in the market, an increased prevalence of oral health conditions, rising awareness among healthcare practitioners, various government initiatives, and a general increase in medication usage. Key trends anticipated in the forecast period involve artificial saliva and saliva substitutes, continuous technological advancements and product innovations, the development of personalized medicine and targeted therapies, the growth of telehealth and remote monitoring, and an increasing prominence of non-invasive therapies.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15700&type=smp

Which Long-Term Drivers Are Expected To Sustain The Generic Central Nervous System Drugs Market?

The growing utilization of chemotherapy in managing cancer is anticipated to fuel the expansion of the xerostomia therapeutics market in the future. In the context of cancer care, chemotherapy involves administering potent drugs designed to eliminate or impede the proliferation of malignant cells. The increasing widespread acceptance of chemotherapy for cancer stems primarily from its efficacy in precisely targeting and eliminating cancerous cells across the body. Xerostomia treatments encompass medications or oral rinses that stimulate saliva, thereby boosting saliva generation and improving taste, which facilitates easier eating and proper nutritional intake for patients. For example, as reported by the US-based government entity, the National Cancer Institute, in January 2022, an estimated 18.1 million cancer survivors resided in the United States, representing 5.4% of the total population. Projections indicate that by 2032, the global number of cancer survivors will reach 22.5 million, marking a 24.4% rise from the current figures. Consequently, the expanding use of chemotherapy in cancer therapy is significantly contributing to the advancement of the xerostomia therapeutics market.

How Is The Generic Central Nervous System Drugs Market Classified By Different Segments?

The xerostomia therapeutics market covered in this report is segmented –

1) By Type: Artificial Saliva Or Saliva Substitutes, Salivary Stimulants

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Drug Stores, Mail Order Pharmacies, Hypermarkets And Supermarkets

3) By End-User: Adult, Pediatric

Subsegments:

1) By Artificial Saliva Or Saliva Substitutes: Oral Sprays, Gels, Lozenges, Mouthwashes

2) By Salivary Stimulants: Prescription Drugs, Over-The-Counter (Otc) Products, Chewing Gums And Lozenges

What Current And Upcoming Trends Are Shaping The Generic Central Nervous System Drugs Market?

Leading companies within the xerostomia therapeutics market are innovating patient-friendly, non-invasive solutions, such as oral sprays, to meet the demand for convenient and effective dry mouth management. These oral sprays enable targeted application to the affected areas of the mouth, supplying essential moisture and lubrication precisely where required. For instance, in July 2023, K Pharmaceuticals, an India-based pharmaceutical firm, introduced Aquoral, a clinically validated oral spray aimed at alleviating dry mouth, also known as xerostomia. This condition can stem from various causes, including medications and illnesses, potentially leading to discomfort, challenges with chewing and swallowing, and other oral health issues. Aquoral provides sustained relief for up to six hours by establishing a durable protective layer over the oral cavity, which reduces moisture evaporation and improves comfort. Unlike conventional water-based treatments that demand frequent reapplication, Aquoral utilizes patented Oxidized Glycerol Triesters (OGT), a plant-derived, lipid-based technology offering superior protection.

Who Are The Primary Market Leaders In The Generic Central Nervous System Drugs Market?

Major companies operating in the xerostomia therapeutics market are Bayer AG, 3M Company, GlaxoSmithKline plc, Colgate-Palmolive Company, Fresenius Kabi AG, Sun Pharmaceutical Industries Ltd., Church & Dwight Co. Inc., Cipla Ltd., Hikma Pharmaceuticals PLC, Lupin Limited, Synedgen Inc., Sunstar Suisse S.A., Advanz Pharma Corp., Pharmascience Inc., Mission Pharmacal Company, Dentaid Ltd., Cyclacel Pharmaceuticals Inc., Parnell Pharmaceuticals Holdings Ltd., Teva Pharmaceutical Industries Ltd., Forward Science Holding Inc., ICPA Health Products Ltd., CCMed Ltd., Bio Cosmetics Laboratories S.L., Quest Products LLC, Acacia Pharma, Saliwell Limited, OraCoat, Oralieve UK Ltd., OraPharma Inc., OraVital Inc

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/xerostomia-therapeutics-global-market-report

Which Regional Markets Are Emerging As Key Centers For The Generic Central Nervous System Drugs Market?

North America was the largest region in the xerostomia therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the xerostomia therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=15700&type=smp

Browse Through More Reports Similar to the Global Generic Central Nervous System Drugs Market 2025, By The Business Research Company

Peptide Therapeutics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/peptide-therapeutics-global-market-report

Liver Diseases Therapeutics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/liver-diseases-therapeutics-global-market-report

Cystic Fibrosis Cf Therapeutics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cystic-fibrosis-cf-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim 30% Off Global Market Reports With Code ONLINE30 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

How Big Is The Xerostomia Therapeutics Market Today And What Is Its Future Size?

The therapeutic market size for xerostomia has experienced consistent growth in the past few years. Its valuation is projected to rise from $2.14 billion in 2024 to $2.24 billion in 2025, resulting in a compound annual growth rate (CAGR) of 4.7%. The surge observed in the historic timeframe is attributed to the escalating cases of xerostomia among the elderly, the proliferation of effective xerostomia products due to research and development, increasing cognizance of products related to xerostomia, a rise in underlying medical conditions, and the growing instance of chronic illnesses.

Expect a consistent surge in the xerostomia therapeutics market size over the next few years. By 2029, it is projected to hit “$2.69 billion, with a compound annual growth rate (CAGR) of 4.7%. Factors such as the wide accessibility of affordable medications, heightened occurrence of oral health ailments, increasing cognizance among healthcare professionals, government-driven initiatives, and burgeoning use of medication account for this growth within the forecast period. The forecast period will significantly be defined by trends like artificial saliva and saliva substitutes, technological progression and product novelty, personalized medicine alongside targeted therapies, telehealth coupled with remote monitoring, and the emergence of non-invasive therapies.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15700&type=smp

Which Industry Forces Are Driving The Xerostomia Therapeutics Market Forward?

The surge in chemotherapy usage in cancer care is projected to drive the xerostomia therapeutics market’s expansion. These powerful drugs, used in chemotherapy, are designed to destroy or stall cancer cell growth. The growing popularity of chemotherapy in cancer care is primarily due to its ability to specifically target and eliminate cancer cells across the body. Saliva-inducing medications or mouthwashes fall under xerostomia therapeutics, improving saliva production and enhancing taste perception, thereby helping patients to eat and maintain proper nutrition. To illustrate, in January 2022, the National Cancer Institute, a US government agency, estimated that there are 18.1 million cancer survivors in the US, accounting for 5.4% of the total population. By 2032, the global number of cancer survivors is expected to reach 22.5 million, reflecting a 24.4% rise from the current estimate. Thus, the rising use of chemotherapy in cancer care is influencing the growth of the xerostomia therapeutics market.

How Does The Xerostomia Therapeutics Market Differ By Segment?

The xerostomia therapeutics market covered in this report is segmented –

1) By Type: Artificial Saliva Or Saliva Substitutes, Salivary Stimulants

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Drug Stores, Mail Order Pharmacies, Hypermarkets And Supermarkets

3) By End-User: Adult, Pediatric

Subsegments:

1) By Artificial Saliva Or Saliva Substitutes: Oral Sprays, Gels, Lozenges, Mouthwashes

2) By Salivary Stimulants: Prescription Drugs, Over-The-Counter (Otc) Products, Chewing Gums And Lozenges

What New Opportunities Are Emerging From Trends In The Xerostomia Therapeutics Market?

Key players in the xerostomia therapeutics market are innovating patient-oriented, noninvasive treatments such as oral sprays to fulfill the need for efficient and easy-to-use solutions to manage dry mouth. Oral sprays provide precise delivery to dry areas in the mouth, offering targeted moisture and lubrication. For example, in July 2023, K Pharmaceuticals, a pharmaceutical firm from India, introduced Aquoral, a clinically tested oral spray aimed at alleviating dry mouth, otherwise known as xerostomia. This condition can be triggered by a range of factors, from medications to diseases, and can result in discomfort, eating and swallowing challenges, and dental health issues. Aquoral aids in providing lasting relief for up to six hours by establishing a durable protective shield over the mouth, minimizing moisture depletion and boosting comfort. Unlike conventional water-based treatments requiring regular reapplication, Aquoral employs proprietary Oxidized Glycerol Triesters (OGT), a lipid-based solution derived from plants, for enhanced protection.

Who Are The Primary Market Leaders In The Xerostomia Therapeutics Market?

Major companies operating in the xerostomia therapeutics market are Bayer AG, 3M Company, GlaxoSmithKline plc, Colgate-Palmolive Company, Fresenius Kabi AG, Sun Pharmaceutical Industries Ltd., Church & Dwight Co. Inc., Cipla Ltd., Hikma Pharmaceuticals PLC, Lupin Limited, Synedgen Inc., Sunstar Suisse S.A., Advanz Pharma Corp., Pharmascience Inc., Mission Pharmacal Company, Dentaid Ltd., Cyclacel Pharmaceuticals Inc., Parnell Pharmaceuticals Holdings Ltd., Teva Pharmaceutical Industries Ltd., Forward Science Holding Inc., ICPA Health Products Ltd., CCMed Ltd., Bio Cosmetics Laboratories S.L., Quest Products LLC, Acacia Pharma, Saliwell Limited, OraCoat, Oralieve UK Ltd., OraPharma Inc., OraVital Inc

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/xerostomia-therapeutics-global-market-report

Which Region Is Likely To Register The Fastest Growth In The Xerostomia Therapeutics Market?

North America was the largest region in the xerostomia therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the xerostomia therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=15700&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Outlook for the Generic Central Nervous System Drugs Market Heading Into 2029?

In recent times, the xerostomia therapeutics market has experienced a consistent expansion. It is projected to increase from $2.14 billion in 2024 to $2.24 billion in 2025, displaying a compound annual growth rate (CAGR) of 4.7%. Reasons for this growth during the historical period include a rise in xerostomia cases within the elderly population, advancement in product research for xerostomia, boosting awareness concerning xerostomia-related merchandise, growing health conditions, and an increased prevalence of chronic illnesses.

It is predicted that the xerostomia therapeutics market will undergo a stable increase in the upcoming years, expanding to “$2.69 billion in 2029, with a 4.7% compound annual growth rate (CAGR).” This forecasted growth can be associated with the readily accessible economical medicines, the ever-growing incidence of oral health issues, heightened awareness among medical professionals, government policy initiatives, and the growing trend of medication use. Noteworthy trends to watch out for during the forecasted period include the rise in artificial saliva and saliva substitutes, advances in technology and product innovation, personalized and targeted therapies, telehealth and distant supervision, and the emergence of non-invasive therapies.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15700&type=smp

Which Factors Are Pushing The Generic Central Nervous System Drugs Market Forward?

The rise in mental health disorders is set to stimulate the expansion of the generic central nervous system (CNS) drug market in the future. These disorders cause significant impairment in a person’s cognitive abilities, emotional handling or behavioral patterns, often associated with distress or dysfunctional behavior in key aspects of life. Generic CNS drugs are pivotal in managing these disorders as they provide accessible and cost-effective treatment choices. For instance, the Health and Social Care Information Centre, a UK federal entity providing data, information, and computer systems for professionals, doctors, and administrators in the social and healthcare sectors, reported in November 2022 that the percentage of 17- to 19-year-olds presumed to have a mental disorder increased from 17.4% in 2021 to 25.7% in 2022. Consequently, the escalating prevalence of mental health disorders is fuelling the growth of the generic CNS drug market.

The xerostomia therapeutics market covered in this report is segmented –

1) By Type: Artificial Saliva Or Saliva Substitutes, Salivary Stimulants

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Drug Stores, Mail Order Pharmacies, Hypermarkets And Supermarkets

3) By End-User: Adult, Pediatric

Subsegments:

1) By Artificial Saliva Or Saliva Substitutes: Oral Sprays, Gels, Lozenges, Mouthwashes

2) By Salivary Stimulants: Prescription Drugs, Over-The-Counter (Otc) Products, Chewing Gums And Lozenges

What Notable Trends Are Shaping The Direction Of The Generic Central Nervous System Drugs Market?

Major firms in the xerostomia therapeutics industry are innovating non-invasive, patient-centric treatments like oral sprays to meet the rising demand for efficient and convenient dry mouth management tools. Oral sprays specifically target and moisten dry mouth areas, providing immediate lubrication and relief in the needed areas. For instance, K Pharmaceuticals, a company established in India, released Aquoral in July 2023- a clinically tested oral spray, to mitigate dry mouth or xerostomia. Various elements such as medicines and diseases cause this condition leading to discomfort, chewing, swallowing troubles, and escalated oral health complications. Aquoral forms a continual protective shield over six hours in the mouth, which lessens the loss of moisture and improves comfort. This plant-derived lipid-based technology, Oxidized Glycerol Triesters (OGT), prevents the need for constant reapplications unlike traditional aqueous-based solutions, providing superior coverage.

Which Organizations Are Driving Progress In The Generic Central Nervous System Drugs Industry?

Major companies operating in the xerostomia therapeutics market are Bayer AG, 3M Company, GlaxoSmithKline plc, Colgate-Palmolive Company, Fresenius Kabi AG, Sun Pharmaceutical Industries Ltd., Church & Dwight Co. Inc., Cipla Ltd., Hikma Pharmaceuticals PLC, Lupin Limited, Synedgen Inc., Sunstar Suisse S.A., Advanz Pharma Corp., Pharmascience Inc., Mission Pharmacal Company, Dentaid Ltd., Cyclacel Pharmaceuticals Inc., Parnell Pharmaceuticals Holdings Ltd., Teva Pharmaceutical Industries Ltd., Forward Science Holding Inc., ICPA Health Products Ltd., CCMed Ltd., Bio Cosmetics Laboratories S.L., Quest Products LLC, Acacia Pharma, Saliwell Limited, OraCoat, Oralieve UK Ltd., OraPharma Inc., OraVital Inc

https://www.thebusinessresearchcompany.com/report/xerostomia-therapeutics-global-market-report

Which Region Is Expected To Experience The Highest Growth In The Generic Central Nervous System Drugs Industry?

North America was the largest region in the xerostomia therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the xerostomia therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=15700&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model